Format

Send to

Choose Destination
Alzheimers Dement. 2015 May;11(5):511-22. doi: 10.1016/j.jalz.2014.05.1754. Epub 2014 Aug 20.

Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease.

Author information

1
Department of Neurology/Alzheimer Centre, VU Medical Centre, Amsterdam, The Netherlands. Electronic address: d.bertens@vumc.nl.
2
Department of Epidemiology and Biostatistics, VU Medical Centre, Amsterdam, The Netherlands.
3
Department of Neurology/Alzheimer Centre, VU Medical Centre, Amsterdam, The Netherlands.
4
Department of Neurology/Alzheimer Centre, VU Medical Centre, Amsterdam, The Netherlands; Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience (MHeNS), Alzheimer Centre Limburg, University Medical Centre, Maastricht, The Netherlands.

Abstract

BACKGROUND:

We investigated the pattern of disease progression in the asymptomatic, mild cognitive impairment (MCI), and dementia stage of Alzheimer's disease (AD).

METHODS:

We selected 284 subjects with AD pathology, defined as abnormal levels of amyloid beta 1-42 (Aβ1-42) in cerebrospinal fluid (CSF). Disease outcome measures included six biomarkers and five cognitive markers. We compared differences in baseline measures and decline over 4 years between the AD stages and tested whether these changes differed from subjects, without AD pathology (N = 132).

RESULTS:

CSF Aβ1-42 reached the maximum abnormality level in the asymptomatic stage and tau in the MCI stage. The imaging and cognitive markers started to decline in the asymptomatic stage, and decline accelerated with advancing clinical stage.

CONCLUSION:

This study provides further evidence for a temporal evolution of AD biomarkers. Our findings may be helpful to determine stage specific outcome measures for clinical trials.

KEYWORDS:

Alzheimer's disease; Asymptomatic; Biomarkers; Cognitive markers; Dementia; Longitudinal; MCI; Observational

PMID:
25150730
PMCID:
PMC4336230
DOI:
10.1016/j.jalz.2014.05.1754
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center